SOLARA
Active Pharma Sciences

Communication Address :
Solara Active Pharma Sciences Limited
Batra Centre
No. 28, Sardar Patel Road, Post Box 2630
Guindy, Chennai - 600 032, India
Tel : +91 44 43446700, 22207500
Fax : +91 44 22350278

October 23, 2019

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code: 541540

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: SOLARA

Dear Sir / Madam,

Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Please find attached press release issued by the Company titled:

"Further updates on Ranitidine Hydrochloride API"

Thanking you,

Yours faithfully,
For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

Encl:- as above

SOLARA ACTIVE PHARMA SCIENCES LIMITED

PRESS **RELEASE**

FOR IMMEDIATE CIRCULATION

SOLARA
Active Pharma Sciences

WWW.SOLARA.CO.IN | BSE:541540 NSE: SOLARA BLOOMBERG: SOLARA: IN | SECTOR: PHARMACEUTICALS

Further Updates on Ranitidine Hydrochloride API

Bangalore, India – October 23, 2019: Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540) today shared further updates to its earlier release dated September 27, 2019 titled **"Press release on Ranitidine Hydrochloride"**. The Company, in September 2019, received request for information from USFDA, EDQM & TGA to provide test data on N-nitrosodimethylamine (NDMA) content in Ranitidine Hydrochloride API and voluntarily suspended production and distribution of Ranitidine for all the markets.

The Company would like to share that TGA[1] , on October 22, 2019, published results of **135 samples** of Ranitidine medications from **10 Australian companies available** in the market. As per the results, out of the 135 batches, **only 24 oral solid dosage batches were found to have levels of NDMA within the acceptable limit of 0.3 ppm and all these batches were produced using the API supplied by Solara.**

These tests were conducted adopting the recently **recommended test methods by USFDA.**

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five globally compliant API facilities, with approvals including the USFDA, EU GMP and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal
Investor Relations Consultant
✉ abhishek.singhal@solara.co.in
✆ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S
Raghavan. V
✉ investors@solara.co.in
✆ +91 44 4344 6700

[1] https://www.tga.gov.au/tga-laboratories-testing-ranitidine-medicines